Like many pharma companies, Pfizer is attempting to eat into the sales of rivals with biosimilars – cheaper near copies of biological drugs that have begun to dominate the prescription medicines ...

Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer also advanced its oncology clinical pipeline in 2024, with several candidates entering late ...

Pfizer is ending the development of its GLP-1 weight loss drug, danuglipron. A patient in a clinical trial experienced a liver injury, potentially due to the drug. Pfizer has a massive pipeline ...

Pfizer is currently assessing the potential divestiture of its hospital drugs unit, a division mainly focused on antibiotics ...

Pfizer Inc. reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance. “Our overall solid first-quarter performance demonstrates our continued focus on ...

Pfizer on Monday said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial. The patient ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...

"Pfizer is proud to bring IXIFI to Canadians ... support program designed to help them navigate their care journey." "Biosimilars are designed to be highly similar to their reference products ...

Get the next trade alert free. Pfizer Inc. PFE is discontinuing development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist being investigated for chronic weight management.